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KEAP1 is a substrate adaptor protein for a CUL3-based E3
ubiquitin ligase. Ubiquitylation and degradation of the antioxi-
dant transcription factor NRF2 is considered the primary func-
tion of KEAP1; however, few other KEAP1 substrates have been
identified. Because KEAP1 is altered in a number of human
pathologies and has been proposed as a potential therapeutic
target therein, we sought to better understand KEAP1 through
systematic identification of its substrates. Toward this goal, we
combined parallel affinity capture proteomics and candidate-
based approaches. Substrate-trapping proteomics yieldedNRF2
and the related transcription factor NRF1 as KEAP1 substrates.
Our targeted investigation of KEAP1-interacting proteins
revealed MCM3, an essential subunit of the replicative DNA
helicase, as a new substrate. We show that MCM3 is ubiquity-
lated by the KEAP1-CUL3-RBX1 complex in cells and in vitro.
Using ubiquitin remnant profiling, we identify the sites of
KEAP1-dependent ubiquitylation inMCM3, and these sites are
on predicted exposed surfaces of the MCM2–7 complex. Unex-
pectedly, we determined that KEAP1 does not regulate total
MCM3protein stability or subcellular localization. Our analysis
of a KEAP1 targeting motif in MCM3 suggests that MCM3 is a
point of direct contact between KEAP1 and theMCMhexamer.
Moreover, KEAP1 associates with chromatin in a cell cycle-de-
pendent fashion with kinetics similar to theMCM2–7 complex.
KEAP1 is thus poised to affect MCM2–7 dynamics or function
rather than MCM3 abundance. Together, these data establish
newfunctions forKEAP1withinthenucleusandidentifyMCM3as
a novel substrate of the KEAP1-CUL3-RBX1 E3 ligase.
Kelch-like ECH-associated protein 1 (KEAP1)3 is a substrate
adaptor protein for a Cullin3 (CUL3)-RBX1 E3 ubiquitin ligase
complex (1–3). Recent studies have described the molecular
architecture andmechanism for theKEAP1-CUL3-RBX1ubiq-
uitylationmachine (4, 5). Themostwell studied and established
substrate of the KEAP1 complex is the NFE2L2 transcription
factor (henceforth referred to as NRF2) (1–3, 6, 7). A
homodimer of KEAP1 tethered to CUL3 via its amino-terminal
bric-a-brac/tramtrack/broad complex (BTB) domains binds to
a single molecule of NRF2, and the C-terminal kelch domains
of a KEAP1 homodimer bind to a high-affinity motif (ETGE)
and a lower-affinity motif (DLG) within the NRF2 protein (2, 8,
9). Under homeostatic conditions, ubiquitylated NRF2 is rap-
idly degraded by the proteasome, having a half-life of less than
30 min (10). KEAP1 acts as a sensor of cellular reduction-oxi-
dation (redox) state through its 27 cysteine residues (6, 11, 12).
The reactive cysteine residues within KEAP1 can be modified
by reactive oxygen species (ROS), which is thought to trigger a
conformational change in the KEAP1 complex (3, 6, 11). As a
result, NRF2 is no longer efficiently degraded and thus accumu-
lates, translocates to the nucleus, and promotes the transcrip-
tion of antioxidant and cytoprotective genes (10, 13, 14). Spe-
cifically, nuclear NRF2 forms heterodimers with small Maf
proteins, and together they bind to the antioxidant response
elements within the promoter region of NRF2 target genes,
which include free radical scavengers, glutathione synthesis
genes, and xenobiotic efflux proteins (7, 10, 15, 16). The up-reg-
ulation ofNRF2 target genesmitigates oxidative stress and con-
fers resistance to a number of toxins, including chemothera-
peutics (7, 13, 17, 18). The KEAP1-NRF2 signaling pathway
serves as the primary defense of the cell against oxidative stress
(13, 14).
Although NRF2 degradation has long been thought to be the
primary function of KEAP1, we have shown that KEAP1 asso-
ciates with a number of interesting and diverse proteins, sug-
gesting previously unknown roles for KEAP1 (19, 20). In sup-
port of this concept, three substrates have recently been
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reported for the KEAP1 E3 ligase: IKBKB (21), PGAM5 (22),
and PALB2 (23). All three substrates contain an ETGE or ESGE
motif that is essential for their interactions with and ubiquity-
lation by KEAP1. Although we have a strong understanding of
the dynamics and regulation of NRF2 as a KEAP1 substrate,
these other substrates are less well studied. IKBKB is reported
to be a KEAP1 substrate targeted for autophagy-mediated deg-
radation, PGAM5 is thought to be ubiquitylated and targeted to
the proteasome, and KEAP1-mediated PALB2 ubiquitylation
regulates its function by blocking its interaction with BRCA1
(21–24). Thus, the KEAP1-CUL3-RBX1 ligase is capable of
ubiquitylating its substrates to regulate substrate stability
through either proteasome-mediated or autophagy-mediated
degradation or to regulate substrate function by directing pro-
tein-protein interactions.
In addition to the vital role the pathway plays in normal phys-
iology, perturbations in KEAP1-NRF2 signaling have been
reported in a variety of diseases, including cancer and inflam-
matory, cardiovascular, and neurodegenerative diseases (25–
34). Most notably, sequencing efforts have determined that
30% of non-small cell lung cancer tumors harbor mutations
in the KEAP1-NRF2 pathway, and 12–15% of non-small cell
lung cancer patient tumors have mutations within KEAP1 (20,
35–38). The high mutation frequency suggests a role for
KEAP1-NRF2 in cancer progression. KEAP1 loss is thought to
promote tumorigenesis through hyperactivation of NRF2,
although little is known about other effects of KEAP1mutation
or loss. A better understanding of KEAP1 substrates would
enhance our understanding of both normal KEAP1 function
and of KEAP1-mutant tumors. We sought to define new
KEAP1 substrates and to determine the function of their ubiq-
uitylation by KEAP1.
Here we identify a subunit of the replicative DNA helicase
minichromosome maintenance 3 (MCM3) as a KEAP1 sub-
strate. We selected it from our set of potential KEAP1 sub-
strates for further study based on its important role in cell cycle
regulation. Interestingly, human MCM subunits do not
undergo ubiquitin-mediated proteolysis during normal prolif-
eration; instead, the chromatin loading of theMCM complex is
tightly controlled during the cell cycle to ensure once-per-cell
cycle genome duplication. MCM complexes are chromatin-
loaded strictly during G1 phase, activated in S phase, and
progressively unloaded as DNA replication forks terminate
(reviewed in Ref. 39–41). The MCM2–7 complex is exten-
sively modified by posttranslational modifications (42–48),
and, in particular, recent studies linked polyubiquitylation of
the MCM7 subunit to MCM unloading in both Saccharomy-
ces cerevisiae and Xenopus laevis (49–52). In S. cerevisiae,
the SCFDia2 ligase ubiquitylates MCM7, and in X. laevis,
MCM7 is ubiquitylated by an unidentified cullin family
member (49, 50). Thus, interaction with and polyubiquityla-
tion by KEAP1 represents a potentially novel form of MCM
regulation. We suggest that our discovery of KEAP1-medi-
ated MCM3 ubiquitylation establishes a physical link
between a key player in the oxidative stress response and
chromosome replication.
Results
Identification ofMCM3as a KEAP1 Substrate—Weused two
complementary strategies to identify proteins ubiquitylated by
the KEAP1-CUL3-RBX1 complex. First, we employed parallel
affinity capture (PAC) mass spectrometry (Fig. 1A) (53). E3
ubiquitin ligases are processive in action: binding, ubiquitylat-
ing and releasing substrates. As such, traditional purification
of E3 ligases often fails to identify the transient interactions of
co-complexed substrates. The PAC approach uses genetic or
pharmacological tools to block substrate degradation, which
results in stabilization of the E3-substrate interaction (53).
HEK293T cells engineered for stable expression of KEAP1
fused with streptavidin binding peptide (SBP) and HA epitope
were grown in stable isotope labeling with amino acids in cell
culture (SILAC)-lightmedium or SILAC-heavymedium before
addition of vehicle or MG132 proteasome inhibitor (Fig. 1A).
Mass spectrometry analysis of streptavidin-purified protein
complexes from these cells revealed SILAC ratios for KEAP1
and KEAP1-associated proteins (Fig. 1B and supplemental
Table S1). As expected, NRF2 abundance increased within the
KEAP1 complex following MG132 treatment (SILAC ratio,
4). The NRF2-related transcription factor NFE2L1 (hence-
forth referred to as NRF1) similarly increased within the
KEAP1 complex following proteasome inhibition, suggesting
that it is also a KEAP1 substrate (SILAC ratio,2). NRF1 is an
establishedKEAP1-associated protein but, surprisingly, has not
been reported previously to be aKEAP1 substrate (54, 55).With
the exception of NRF2 and NRF1, PAC-based analysis of the
KEAP1 protein complex did not reveal new putative substrates.
PGAM5 is ubiquitylated by KEAP1 and targeted for protea-
some-dependent degradation (22). Unexpectedly, PGAM5 did
not accumulate in cell lysates or on KEAP1 following protea-
some inhibition. Additionally, other high-confidence KEAP1-
interacting proteins that contain an E(T/S)GE motif also did
not show increased binding to KEAP1 with proteasome
inhibition.
We hypothesized that, although successful for identifying
rapidly catalyzed substrates, the PAC-basedmethodmay fail to
reveal KEAP1 substrates with slower rates of ubiquitylation.
Additionally, by design, the PAC method does not identify E3
substrates that are not bound for the proteasome. Therefore, in
a second approach, we interrogated KEAP1-interacting pro-
teins that contain an ETGE or ESGE motif. Specifically,
SBPHA-KEAP1 was affinity-purified fromHEK293T cells over
a time course of MG132 treatment. Co-complexed proteins
were quantified by LI-COR-based immunoblotting. Two pat-
terns were observed. The class 1 proteins NRF1 and NRF2
increased rapidly in whole cell lysates and within the purified
KEAP1 protein complex (5-fold and 18-fold, respectively)
(Fig. 1, C and D). Class 2 proteins include the known KEAP1
substrate PGAM5 as well as MCM3, SLK, and MAD2L1.
Although the steady-state abundances of these proteins were
not affected by MG132 treatment, they reproducibly demon-
strated amodest increase in KEAP1 binding (2-fold) between
4 and 6 h of MG132 treatment. DPP3, another ETGE-contain-
ing KEAP1 interactor, did not fall into either class. Rather, it
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decreased modestly within the KEAP1 complex during protea-
some inhibition.
Although both NRF1 and NRF2 responded rapidly to
proteasome inhibition, NRF2 is the only KEAP1 substrate
that robustly accumulated in response to treatment with a
ROS mimetic (sulforaphane) or KEAP1-CUL3 antagonist
(MLN4924, bardoxolone methyl (CDDO-me)) (Fig. 1E). Col-
lectively, these results suggest two distinct classes of putative
KEAP1 substrates: NRF1 and NRF2, which are short-lived,
stress-responsive proteins that are rapidly turned over by the
proteasome, and a second, more stable and higher abundance
class of KEAP1 substrates comprised of PGAM5, MCM3, SLK,
and MAD2L1. We chose MCM3, a member of the essential
DNA replicative helicase, for further study based on its impor-
tant role in cell cycle regulation.
Biochemical Analysis of the KEAP1-MCM3 Complex—Hav-
ing previously identified MCM3 as a high-confidence KEAP1-
interacting protein by affinity purification (AP)/MS (19, 20) and
now as a putative substrate (Fig. 1, C and D), we sought to
validate and determine the localization of this interaction. We
first conducted a reciprocal MCM3 IP/MS experiment with
ectopically expressed FLAG epitope-tagged MCM3 and
detected endogenous KEAP1 in addition to all expected
MCM3-associated proteins, largely those important for DNA
replication (Fig. 2A). We also detected KEAP1 interaction with
the MCM complex by endogenous co-immunoprecipitation
using antibodies to MCM3 or MCM2 (another subunit of the
MCM2–7 heterohexameric complex) (Fig. 2, B and C). Next,
we expressed a KEAP1 fusion to a biotin ligase proximity detec-
tor, BirA*, and tested MCM subunits for in vivo biotinylation.
We detected biotin-stimulated modification of both endoge-
nous MCM3 and MCM2 only in cells expressing the KEAP1-
BirA* fusion, demonstrating its close proximity to the MCM
hexamer (Fig. 2D). We next assessed where in the cell KEAP1
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and MCM3 interact. Immunofluorescence analysis using
antibodies against MCM3 in cells stably expressing VENUS-
KEAP1 revealed that MCM3 was mainly nuclear, but a small
fraction of MCM3 antibody reactivity diffusely localized to the
cytosol, in contrast to VENUS-KEAP1, which was mainly cyto-
plasmic with a small pool in the nucleus (Fig. 2E). To test in
which compartment(s) KEAP1 and MCM3 associate, we per-
formed an in situ proximity ligation assay (PLA) using primary
antibodies for KEAP1 andMCM3. Fig. 2F shows representative
images for this assay, demonstrating that KEAP1 and MCM3
are in close proximity to one another in both the nucleus and
cytoplasm. Using subcellular fractionation followed by West-
ern blotting, we observed that a small fraction of KEAP1 was
indeed in the nucleus, in agreement with our microscopy anal-
ysis and other reports that 5% of KEAP1 is nuclear (Fig. 2G)
(56).
MCM3 Is a KEAP1 Substrate for Ubiquitylation in Vivo and
in Vitro—Next we tested whether KEAP1 directly ubiquitylates
MCM3. Under near-denaturing conditions, FLAG-MCM3 or
FLAG-NRF2 was immunoprecipitated from HEK293T cells
expressing control GFP or KEAP1. Western blotting analysis
showed strong induction of MCM3 ubiquitylation by KEAP1,
similar to the positive control NRF2 (Fig. 3, A and B). Recipro-
cally, siRNA-mediated silencing of KEAP1 suppressed ubiqui-
tylation of FLAG-MCM3 (Fig. 3C). The degree of KEAP1
silencing by the three independent siRNAs strongly correlated
with loss of MCM3 ubiquitylation. To evaluate the ubiquityla-
tion of endogenous MCM3, we immunoprecipitated MCM3
under near-denaturing conditions from cells transfected with
siRNAs targeting KEAP1 or CUL3. Both KEAP1 and CUL3
silencing suppressed ubiquitylation of endogenousMCM3 (Fig.
3D). These data demonstrate that the KEAP1-CUL3-RBX1
ligase is responsible for themajority ofMCM3ubiquitylation in
proliferating cells. As expected, ubiquitylation of MCM3 by
KEAP1 required MCM3-KEAP1 physical interaction. Specifi-
cally, we mutated the ETGE motif within MCM3 to EAAE and
found that thismutant was not ubiquitylated by KEAP1 and did
not bind KEAP1 (Fig. 3, E and F). Together, these data suggest
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that the KEAP1-CUL3 complex directly ubiquitylates MCM3.
To confirm this, an in vitro ubiquitylation assay was performed.
The KEAP1-CUL3-RBX1 complex was sufficient to ubiquity-
late MCM3 (Fig. 3G).
To identify the sites of ubiquitylation within MCM3, and
specifically those that respond to KEAP1, we performed ubiq-
uitin remnant profiling on immunopurified MCM3 complexes
from control cells or cells overexpressing KEAP1. Specifically,
tryptic peptides from FLAG-MCM3 complexes were subjected
to ubiquitin remnant IP followed by LC/MS-MS. This method
uses an antibody specific for the ubiquitin remnant left on the
ubiquitylated lysine following tryptic digestion. The results
(Fig. 4A) further support ourWestern blotting data that KEAP1
indeed ubiquitylatesMCM3.Using a 3-fold arbitrary threshold,
six lysine residues were identified as responsive to KEAP1-de-
pendent ubiquitylation: Lys-229, Lys-270, Lys-283, Lys-351,
Lys-435, and Lys-748 (Fig. 4A). Of the ubiquitylated lysines
mapped, Lys-435 showed the greatest -fold increase by KEAP1.
This site was also found to be differentially ubiquitylated in an
unbiased screen for cullin ring ligase substrates (57). To visual-
ize these lysines on the structure of the MCM2–7 complex, we
used protein structuralmodeling.HumanMCM3was threaded
around a homologous archaeal MCM protein (58) and super-
imposed over a published model of the yeast MCM2–7 hetero-
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hexamer (59). The lysines observed to be most ubiquitylated in
response to ectopic KEAP1 were found to be on predicted
exposed surfaces of the C-terminal domain in MCM3 (Fig. 4, B
and C).
KEAP1 Does Not Regulate MCM3 Levels, Subcellular Local-
ization, or MCM2–7 Complex Formation—After identifying
MCM3 as a novel KEAP1 substrate, we sought to determine the
function of this ubiquitylation. First, we tested whether KEAP1
targetsMCM3 for proteasome-mediated degradation as it does
its well known substrate NRF2. KEAP1 manipulation did not
affect steady-state levels of total cellular MCM3. Specifically,
KEAP1 knockdown, deletion, overexpression, or chemical
antagonism caused no changes in total MCM3 protein levels,
whereas all of these perturbations affected NRF2 levels (Fig. 5,
A–D). Attempts to determine whether KEAP1 loss affects
MCM3 half-life were hampered by the extremely long MCM3
half-life. A very long (30-h) chase with the protein synthesis
inhibitor cycloheximide did not yield an appreciable change in
MCM3 levels (Fig. 5F), in agreement with a report that showed
that the MCM complex had a half-life of 24 h in vivo (60).
Treatment with the proteasome inhibitor bortezomib also did
not stabilize MCM3 over the course of 8 h, in agreement with
KEAP1-CUL3-RBX1 not targetingMCM3 for proteasome-me-
diated degradation (Fig. 5D). Similarly, treatment with the lys-
osomal inhibitor chloroquine did not stabilize MCM3 over an
8-h time course, supporting the conclusion that the KEAP1-
CUL3-RBX1 ligase is not targeting MCM3 for lysosome-medi-
ated degradation (Fig. 5E).
Next we tested whether KEAP1 could be ubiquitylating
MCM3 to affect its subcellular localization. Using immunoflu-
orescence in HEK293T cells transiently transfected with
KEAP1, we found no difference in the localization of endoge-
nous MCM3, which remains largely diffuse in the nucleus (Fig.
5H, compare cells expressing KEAP1 in red to those not
expressing). We also expressed increasing amounts of exoge-
nous KEAP1 and assayed the amounts of MCM3 in the nuclear
and cytoplasmic compartments and found no difference in the
amount of MCM3 in either compartment, suggesting that
KEAP1 does not regulate total MCM3 subcellular localization
(Fig. 5G).
The ability of MCM3 to associate with the other members of
the MCM2–7 heterohexamer was evaluated by immunopre-
cipitating either WT FLAG-MCM3 or the KEAP1-deficient
binding mutant (FLAG-MCM3 EAAE) and probing with anti-
MCM2. A comparable amount of MCM2 associated with both
forms of MCM3, suggesting that KEAP1 binding and ubiquity-
lation do not regulateMCM3 incorporation into theMCM2–7
hexamer (Fig. 3F). Furthermore, MCM3 was associated with
the other MCM proteins at similar levels in the presence or
absence of KEAP1 siRNA knockdown (data not shown).
KEAP1-dependent Ubiquitylation Is Not Responsive to
Treatment with DNA-damaging Agents, ROS Mimetics, or
Autophagy—As DNA damage by etoposide was recently
reported to lead to increased phosphorylation and ubiquityla-
tion of a number of sites in subunits of the MCM2–7 complex
(61), including three ubiquitylation sites within MCM3, we
examined whether KEAP1 could be one of the E3 ligases that
ubiquitylate MCM3 in response to DNA damage. We found,
however, that overnight treatment with a panel of DNA-dam-
aging agents (etoposide, gemcitabine, and 4-Nitroquinoline
1-oxide (4NQO)) did not strongly affect the MCM3-KEAP1
interaction (Fig. 6A) or KEAP1-dependent ubiquitylation of
MCM3 but did activate phospho-Chk1, amarker of DNA dam-
age (Fig. 6B). These data suggest that KEAP1 is not the ligase
modifying MCM3 in response to etoposide-mediated DNA
damage.
The ability of KEAP1 to act an as efficient substrate adaptor
for NRF2, its well known substrate, relies on the redox state of
the cell because, during oxidative stress, KEAP1 undergoes
electrophilic attack by ROS and is placed in a conformation no
longer favorable to target NRF2 (3, 6, 11, 12, 62–64). To test
whether MCM3 is also a ROS-dependent substrate of KEAP1,
we employed surrogate compounds (sulforaphane and tert-bu-
tylhydroquinone (tBHQ)) that mimic ROS by attacking the
reactive cysteines within KEAP1. These drugs are widely used
as NRF2 agonists, although whether these inhibit NRF2 ubiq-
uitylation or block release of ubiquitylated NRF2 is debated.
Here we find that treatment with these compounds stabilizes
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FIGURE 4.Mapping the KEAP1-dependent ubiquitylation sites in MCM3.
A, HEK293T cells were transfected with plasmids encoding FLAG-MCM3 with
or without the SBPHA-KEAP1 plasmid, and a near-denaturing FLAG IP was
performed as in Fig. 3. A tryptic digest and ubiquitin remnant IP were then
performed, followed by LC/MS-MS on the resultant peptides. Ubiquitylated
peptides of MCM3 detected are plotted as mean  S.E. MS1 peak areas of
three biological replicate experiments. Black columns are lysine residues that
increased beyond an arbitrary threshold of 3-fold increase in the presence of
SBPHA-KEAP1 (supplemental Table S3). B, protein structural modeling of
human MCM3 (Uniprot code P25205-1) threaded around an archaeal MCM
structure (PDB code 3F9V). The KEAP1-modified lysines detected in A are
shown as green spheres. C, protein structural modeling of humanMCM3 from
B superimposed over the published model of the yeast MCM2–7 complex
(59). The KEAP1-modified lysines detected in A are shown as green spheres. A
top-down view (left panel) and side view (right panel) are shown. CTD, C-ter-
minal domain; NTD, N-terminal domain.
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NRF2 but does not ablate KEAP1-dependent ubiquitylation of
either NRF2 or MCM3 (Fig. 6, C and D). Together, these data
suggest that the ubiquitylation of MCM3, like NRF2, is not
inhibited by sulforaphane or tBHQ.
AsMCM3, along with other important DNA replication fac-
tors, was recently reported to undergo autophagy-mediated
degradation, we tested whether KEAP1 could be ubiquitylating
MCM3 to target it for lysosomal degradation (65). We found
that treatmentwith a lysosome-mediated degradation inhibitor
(chloroquine, 100 M for 8 h) or an autophagy activator (rapa-
mycin, 10 M for 8 h) did not affect KEAP1-dependent ubiqui-
tylation of MCM3 but did augment LC3 I/II conversion, a
marker of autophagy (Fig. 6E). These data suggest that KEAP1
is not targeting MCM3 for autophagy-mediated degradation.
KEAP1 Associates with Chromatin in a Cell Cycle-dependent
Fashion—Our detection of KEAP1-MCM3 association in the
nuclei of actively proliferating cells suggested that KEAP1 may
associate with MCM3 during a normal cell cycle. MCM3 is
chromatin-loaded as part of the MCM2–7 complex during G1
phase and unloaded as DNA replication completes throughout
S phase. To examine whether KEAP1 associates with chroma-
tin in a cell cycle-dependent fashion, HeLa cells were synchro-
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nized, and lysates were collected during G1 and early S phase.
The lysates were fractionated into chromatin and soluble frac-
tions and immunoblotted for KEAP1, MCM3, and fraction-
ation and loading controls. Strikingly, we found that KEAP1
loaded onto chromatin during G1 phase asMCM3 did (Fig. 7A,
loading is seen at the 4- to 10-h time points, chromatin frac-
tion). To investigate when KEAP1 also unloads from the chro-
matin, HeLa cells were synchronized in early S phase, and
lysates were collected from S to M phase. These lysates were
fractionated into chromatin and whole cell fractions and
probed for KEAP1, MCM3, and fractionation and loading con-
trols. KEAP1 unloaded in G2 phase, similar to MCM3, but the
unloading of KEAP1was slightly behind that ofMCM3 (Fig. 7B,
unloading is seen at the 6- to 10-h time points, chromatin frac-
tion). Thus, KEAP1 associates with DNA in a cell cycle-depen-
dent fashion, and KEAP1 is at the right place at the right time
during the cell cycle to regulate the MCM complex.
In an asynchronous population, KEAP1 bound MCM3 pre-
dominantly in the soluble fraction with a weaker association on
chromatin (Fig. 7C). This observation is consistent with the fact
that most of the cellular MCM is soluble, and only a fraction is
chromatin-loaded. To test where in the cell this KEAP1-depen-
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dent ubiquitylation occurs, cells expressing FLAG-MCM3 and
either GFP or KEAP1 were fractionated into chromatin and
soluble fractions, subjected to FLAG (MCM3) IPs in both frac-
tions, and probed byWestern blotting for ubiquitin onMCM3.
Most ubiquitylation of MCM3 by KEAP1 was seen in the solu-
ble fraction. Ubiquitylation of MCM3 in the chromatin-bound
fraction was detectable, although only during proteasome inhi-
bition (Fig. 7D). Therefore, KEAP1-dependent ubiquitylation
of MCM3 occurs in both the chromatin and soluble fractions.
Discussion
Through its ubiquitin ligase activity, KEAP1 serves as a sen-
sor and molecular switch for the cellular response to oxidative
stress. Here we provide data that support the emerging concept
of NRF2-independent functions for KEAP1. To date, in addi-
tion to NRF2 signaling and the coordinated antioxidant
response, KEAP1 has been shown to regulate NF-B signaling
through its degradation of IKBKB to target the mitochondrial
membrane phosphatase PGAM5 for proteasome-mediated
degradation and to regulate DNA break repair through degra-
dation-independent ubiquitylation of PALB2 (21–23). Our
analyses here establish a fourthNRF2-independent function for
KEAP1 and raise the additional possibility that KEAP1 regu-
lates cell cycle progression and/or genome stability through
ubiquitylation of MCM3.
Herewe focused on a biochemical assessment of KEAP1 sub-
strates in general and on definingMCM3 as a KEAP1 substrate
in particular. Our future studies will delve into the role of
KEAP1 in MCM3 function or dynamics. Our present data sug-
gest that KEAP1 interacts with MCM3 when it is in the
MCM2–7 hexameric complex. We detected KEAP1 in MCM2
immunoprecipitates, and, further, we observed biotinylation of
MCM2 by the BirA*-tagged KEAP1. Together, these data sug-
gest that KEAP1 interacts with the full MCM2–7 hexamer (e.g.
Fig. 2C). Moreover, we detected KEAP1-mediated MCM3
ubiquitylation in both the soluble and chromatin-bound frac-
tions (Fig. 7D). The association of KEAP1 with chromatin dur-
ing S phase in a pattern that closely follows MCM loading and
unloading is also consistent with KEAP1 associating with the
MCM complex rather than monomeric MCM3 because only
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the MCM complex is loaded for replication and not individual
subunits (66).We thus favor the notion thatKEAP1 impacts the
replication function of theMCM complex, although we cannot
yet rule out KEAP1 involvement in a novel non-replication role
for MCM3, as has been reported for other individual MCM
subunits (67, 68).
The high-affinity KEAP1-targetingmotif (ETGE) is uniquely
found in MCM3 and not in the other five MCM subunits, sug-
gesting that MCM3 is at least one direct point of contact
between the MCM complex and KEAP1. MCM4 contains the
lower-affinity DLG binding motif for KEAP1, raising the possi-
bility for a second point of contact. All six subunits of the
human MCM2–7 heterohexamer have been reported to be
ubiquitylated in cells (69). It is thus possible that KEAP1 ubiq-
uitylates additional MCM proteins. Based on the S. cerevisiae
and Drosophila melanogaster MCM complexes, we presume
that human MCM3 is adjacent to both MCM5 and MCM7 in
the hexamer (70, 71). MCM5 constitutes one side of the
MCM2/5 “gate” where the MCM ring opens to allow double-
stranded DNA to pass during MCM loading in G1 phase (72,
73). KEAP1 could modulate MCM loading by regulating con-
formational changes at the MCM2/5 interface. MCM3 is the
subunit that directly contacts the helicase activator complex
GINS, which only associates withMCMduring helicase activa-
tion and fork progression (71). KEAP1-mediated MCM3 ubiq-
uitylation could impact helicase activation either globally or at a
subset of origins. Interestingly, polyubiquitylation of the
MCM7 subunit in both S. cerevisiae and X. laevis is associated
with replication termination and MCM unloading (49, 50, 52)
but not changes in MCM7 stability. The KEAP1 interaction
with MCM3 could also impact MCM unloading. KEAP1 could
thus link ROS sensing to the control of MCM chromatin load-
ing, to activation of MCM-dependent DNA unwinding, or to
MCM unloading during S phase as a means to preserve DNA
integrity and genome stability.
Human MCM complexes undergo cell cycle-dependent
phosphorylation and sumoylation (46), and it is certainly pos-
sible that additional E3 ubiquitin ligases participate with
KEAP1 in MCM control. Nonetheless, KEAP1 is clearly the
major MCM3 E3 ubiquitin ligase in actively proliferating cells
(Fig. 3). Our data so far suggest that KEAP1 binds and ubiqui-
tylates only a subset of the total MCM3 molecules and likely
regulates their activity through alteringMCM2–7 protein-pro-
tein interactions or helicase activity. Future work will explore
not only the molecular consequences of KEAP1-mediated
MCM ubiquitylation but also under what cellular circum-
stances KEAP1 may be stimulated to ubiquitylate MCM3. Our
discovery that KEAP1 associates with chromatin during S
phasemay reflect a novel nuclear role for KEAP1 inmonitoring
replication fork progression and perhaps coordinating origin
firing or replisome activity with cellular redox state. If so, then
the KEAP1-MCM interaction represents a novel, nuclear role
for KEAP1 outside of NRF2 regulation, emphasizing the
breadth of KEAP1-regulated cellular events.
We have previously defined a static KEAP1 protein interac-
tion network and demonstrated that it is enriched for proteins
containing the KEAP1 binding motif, E(T/S)GE (19, 20).
Although the ETGE motif in NRF2 has been established as a
KEAP1 degron therein, and several ETGE-containing proteins
have been shown to activate NRF2 through competitive bind-
ing to KEAP1 (74, 75), the function of the interactions between
KEAP1 and these other E(T/S)GE-containing proteins
remained largely unknown. In this study, we have combined
PAC proteomics to capture substrates and annotated them
against what we identified in our prior studies to be high-con-
fidenceKEAP1 interactors.Our data suggest that, in addition to
MCM3, which we validated as a KEAP1-CUL3-RBX1 substrate
here, we may have also discovered NRF1 as a novel KEAP1
substrate. NRF1 has been shown previously to bind KEAP1, but
KEAP1 was shown not to be responsible for targeting NRF1 to
the endoplasmic reticulum membrane or regulating an artifi-
cial reporter of NRF1-driven transcription (54, 55). To the best
of our knowledge, our study is the first report that NRF1 is a
putative KEAP1 substrate for proteasome-mediated degrada-
tion. We observe NRF1 accumulating with proteasome inhibi-
tion in both whole cell lysates and in the KEAP1 complex by
both AP/MS and AP-Western blotting. In-cell and in vitro
ubiquitylation assays will be important to confirm the substrate
status of NRF1. Our findings neither confirm nor rule out
whether MAD2L1, SLK, DPP3, TSC22D4, FAM117B, or other
ETGE-containing KEAP1 interactors are bona fide substrates.
Because we and others have now demonstrated that KEAP1-
CUL3-RBX1 substrates may not be turned over by the protea-
some (23), the substrate status of each of these interactors will
need to be evaluated individually.
Here we broadly defined two classes of KEAP1 substrates:
class I, comprised of NRF2 and, potentially, NRF1 and IKBKB,
and class II, comprised of PGAM5, MCM3, and, potentially,
PALB2, MAD2L1, and SLK (although not detected in our MS
data, IKBKB and PALB2 have been validated by others in the
field). These classes of substrates can likely be further charac-
terized by whether or not the KEAP1 complex targets them for
degradation and whether that degradation occurs via the pro-
teasome or the lysosome. Additionally, the presence of both the
DLG and ETGEmotifs in the rapidly degraded class I substrates
(NRF2, IKBKB, and NRF1) suggest that KEAP1-CUL3-RBX1
substrate dynamics may be governed by the number and/or
types of degrons within a given substrate. This pattern is in
contrast to the class II substrates PGAM5, PALB2, andMCM3,
which contain only the E(T/S)GE motif. These proteins are
generally longer-lived than class I proteins, and their ubiquity-
lation by KEAP1 may be unrelated to their stability. Thus,
whether a KEAP1-CUL3-RBX1 substrate is marked for degra-
dation by ubiquitylation and the dynamics of that degradation
may be in part dependent on the presence of a DLGmotif. The
stoichiometry of the class II substrates PGAM5, PALB2, and
MCM3 within the KEAP1 complex is not known. Whether
thesemay contain a secondKEAP1 bindingmotif that acts sim-
ilarly to the DLG and positions these substrates for ubiquityla-
tion by theKEAP-CUL3-RBX1machinerymerits further study.
This work is important from a basic biology standpoint
because little is known about NRF2-independent functions for
this redox-sensitive E3 ligase. Additionally, this is clinically rel-
evant because a more complete understanding of this pathway
is essential to treating patients harboringKEAP1mutations and
to fully grasping the impact of chemically altering the activity or
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substrate interface of KEAP1. Furthermore, this work provides
a previously unappreciated link between KEAP1, genome sta-
bility, and cell cycle progression.
Experimental Procedures
Tissue Culture, Treatments, Transfections, and Small Inter-
fering RNAs—HEK293T, HDF-Tert, and HeLa cells were
obtained from the American Type Culture Collection. The cell
lines were passaged for no more than 3 continuous months
after resuscitation. HDF-Tert, HEK293T, and HeLa cells were
grown in DMEM supplemented with 10% FBS and 1% penicil-
lin/streptomycin in a 37 °C humidified incubator with 5% CO2.
Mouse embryonic fibroblasts (MEFs) were cultured in Iscove’s
modified Dulbecco’s medium supplemented with 10% FBS and
1% penicillin/streptomycin. The KEAP1 and NRF2 knockout
MEFs were kindly provided by Thomas Kensler and Nobunao
Wakabayshi. Drugs used for cell treatments were acquired as
follows: MG132 (Calbiochem), bortezomib (SelleckChem),
tert-butylhydroquinone (Sigma), sulforaphane (Sigma), etopo-
side (Sigma), chloroquine (Sigma), and gemcitabine (Sigma).
For transient transfections, cDNA expression constructs were
transfected in HEK293T cells using Lipofectamine 2000 (Life
Technologies) for 24 h before harvest. Transfection of siRNA
(20 nM) in HEK293T cells was performed with Lipofectamine
RNAiMAX (LifeTechnologies). Transfection of siRNA inHeLa
cells was done with either Dharmafect (50 nM) or Lipo-
fectamine RNAiMAX (20 nM). siRNA sequences were as fol-
lows: control, CGUACGCGGAAUACUUCGATT; KEAP1-A,
GGGCGUGGCUGUCCUCAAU; KEAP1-B, CAUGUGAU-
UUAUUCUUGGAUACCUG; KEAP1-C, UGGCUGUCCU-
CAAUCGUCUCCUUUA; CUL3-A, GGUCUCCUGAAUAC-
CUCUCAUUAUU; and CUL3-B, GAAUGUGGAUGUCAG-
UUCACGUCAA.
Immunoprecipitations, Affinity Pulldowns, and Western
Blotting—These experiments were performed as described pre-
viously (74) with minor modifications. Briefly, for streptavidin
and FLAG affinity and immune purification, cells were lysed in
0.1% Nonidet P-40 lysis buffer (10% glycerol, 50 mM Tris-HCl,
150 mM NaCl, 2 mM EDTA, 0.1% Nonidet P-40 supplemented
with protease inhibitor mixture (Thermo Scientific) and phos-
phatase inhibitor (Thermo Scientific), 10 mM N-ethylmaleim-
ide, and 250 units Benzonase (Sigma)) and then passed through
a 26.5-gauge needle three times. The cell lysateswere cleared by
centrifugation and incubated with streptavidin resin (GE
Healthcare) or FLAG resin (Sigma) before washing with lysis
buffer and eluting with NuPAGE 4 SDS loading buffer (Life
Technologies). For siRNA knockdown, HEK293T cells were
transiently transfected and lysed in RIPA buffer (1% Nonidet
P-40, 0.1%SDS, 0.25% sodiumdeoxycholate, 150mMNaCl, 10%
glycerol, 25 mM Tris, and 2 mM EDTA supplemented with pro-
tease inhibitormixture, phosphatase inhibitor, andN-ethylma-
leimide) 60–72 h post-transfection. For BirA* affinity purifica-
tion, HEK293T cells were pretreated with 50 M biotin for 2–4
h and lysed in supplemented RIPA buffer, and cleared lysates
were subjected to streptavidin AP as above and eluted with a
1:1:1:1 mixture of 1 M DTT, 4 SDS loading buffer, 50 M
biotin, and RIPA buffer. For endogenous IP (Fig. 2, B and C),
HEK293T cells were lysed in co-IP buffer (50 mM HEPES (pH
7.2), 33 mM potassium acetate, 1 mM MgCl2, 1 mM ATP, 0.1%
Nonidet P-40, 5 mM CaCl2, and 10% glycerol with protease and
phosphatase inhibitors), then treatedwith 10 units of S7micro-
coccal nuclease (Roche), sonicated, and cleared by centrifuga-
tion. Samples were rotated with MCM2 antibody or control
rabbit IgG, followed by rotation with protein A-Sepharose
(Roche), and then washed three times with co-IP buffer and
eluted with 2 SDS loading buffer, 5% 2-mercaptoethanol
(Sigma), and boiling for 10 min. Lysates were resolved on
4–12% SDS-PAGE gradient gels (Invitrogen), transferred to
nitrocellulose or PVDF membranes, and probed using the fol-
lowing antibodies: anti-MCM3 (Bethyl, A300-192A), anti-
KEAP1 polyclonal (ProteinTech, Chicago IL), anti-FLAG M2
monoclonal (Sigma), anti-HA monoclonal (Roche), anti-
MAD2L1 (Bethyl, Montgomery TX, A300-301A), anti-SLK
(Bethyl, A300-499A), anti--actin polyclonal (Sigma, A2066),
anti--tubulin monoclonal (Sigma, T7816), anti-DPP3 poly-
clonal (Abcam, Cambridge, MA, 97437), anti-GFP (Abcam,
ab290), anti-NRF2 H300 polyclonal (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-PGAM5 polyclonal (Abcam,
126534), anti-NRF1 polyclonal (Santa Cruz Biotechnology,
D5B10), anti-MCM2 polyclonal (Bethyl, A300-191A), anti-Pan
MCM (a kind gift from D. MacAlpine, Duke University), and
anti-VSV polyclonal (Bethyl, A190-131A). Biotinylated pro-
teins associated with BirA* AP blots were detected using fluo-
rescently labeled streptavidin (IRDye 680CW-LI-COR). Pro-
tein quantification was performed in the LI-COR imaging suite
(Image Studio Lite), where all blots were determined to be in
the linear range by the software.
Cell Fractionations and Cell Synchronization—HeLa cells
were synchronized with a double thymidine block in early S
phase by treatment with 2 mM thymidine (Sigma) for 18 h,
washout for 9 h, and readdition of 2 mM thymidine for an addi-
tional 17 h. HeLa cells were synchronized inM phase by double
thymidine/nocodazole block: first, the double thymidine block
(as above, with 24 h of 2 mM thymidine, 6 h of release, and
readdition of thymidine for 18 h), and then cells were released
into freshDMEMcontaining 100 ng/ml nocodazole for 8–12 h.
In each case, cells were washed twice with warm medium and
released into fresh DMEM. Chromatin fractionation was per-
formed by gentle lysis with CSK buffer (0.5% Triton X-100, 300
mM sucrose, 10 mM PIPES, 100 mM NaCl, and 2 mM EDTA)
supplemented with protease and phosphatase inhibitors for 20
min on ice. Lysates were centrifuged at 900 g for 5min at 4 °C
to pellet the nuclei. Soluble fractions were transferred to new
tubes. The nuclei were resuspended in CSK buffer containing
10 units DNase (RQ1, Promega) for 10 min at room tempera-
ture and pelleted at 900  g for 5 min at 4 °C. The remaining
nuclei were washed once with CSK buffer, and the first DNase
digest and the wash were pooled. Nuclear proteins solubilized
by DNase digest were the chromatin fraction.
Plasmids, Expression Vectors, and Site-directed Muta-
genesis—Expression constructs in the SBPHA backbone were
generated with standard PCR techniques as described previ-
ously (20). The expression constructs for MCM3 and NRF2
were obtained from Open Biosystems and cloned into a
custom gateway lentiviral vector (pHAGE-CMV-FLAG-
DEST). MCM3 and NRF2 were obtained as orfeome entry
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clones and gateway-cloned into pHAGE-CMV-FLAG-DEST.
The MCM3 EAAE alanine mutant was created using PCR-
basedmutagenesis (Q5 site-directedmutagenesis kit,NewEng-
land Biolabs) and sequence-verified before use.
Cell-based Ubiquitylation Experiments—These experiments
were performed as reported previously (20) with few modifica-
tions. Briefly, HEK293T cells were transfected with VSV-UB,
FLAG-NRF2, or FLAG MCM3 and either SBPHA-KEAP1 or
SBP-GFP as a control so that each condition received the same
mass of DNA. The cells were lysed under near-denaturing con-
ditions in 1% SDS lysis buffer (1% SDS, 150mMNaCl, and 2mM
EDTA) and boiled at 90 °C for 10 min. SDS lysis buffer was
diluted 1:10 in cold 0.5% Nonidet P-40 lysis buffer supple-
mented with protease, phosphatase, and deubiquitylase inhib-
itors, and the lysates were cleared by centrifugation. FLAG IPs
were carried out by incubating lysates with FLAG resin for 1–4
h at 4 °C, followed by washing three times in lysis buffer and
eluting with 4 SDS loading buffer and DTT.
In Vitro Ubiquitylation Experiments—For in vitro ubiquity-
lation studies, SBPHA-KEAP1was generated using a TNT assay
(Promega), andMCM3was purified fromHEK293T cells stably
expressing FLAG-MCM3 using 1% Triton-X lysis buffer (as
described above for immunoprecipitations but with 500 mM
NaCl). For the in vitro ubiquitylation assay, KEAP1 was mixed
with recombinant humanE1 (Ube1, BostonBiochem),UbcH5B
(E2, Boston Biochem), CUL3-RBX1 (co-expressed in Esche-
richia coli as GST-Rbx1 and His-CUL3 fusions and purified
sequentially over HiTRAP nickel-nitrilotriacetic acid (GE
Healthcare) and glutathione-Sepharose (GE Healthcare) and
proteolytically cleaved off the resin using thrombin (Sigma),
followed by size exclusion chromatography over a Superdex-
200 16/60 column (GE Healthcare)), ubiquitin (Boston
Biochem), and FLAG-tagged MCM3 in buffer containing 25
mM HEPES (pH 8.0), 5 mM MgCl2, 2 mM DTT, and 4 mM ATP.
Ubiquitylation was carried out for 20 min at 30 °C, and the
products were analyzed by Western blotting with anti-FLAG
antibody.
Protein Structural Modeling—The crystal structure of an
archaeal MCM from Sulfolobus solfataricus (PDB code 4FDG)
was identified as a template for predicting the atomic structure
of human MCM3 by HHpred (PMID 15531603), and the ho-
mology model was generated using MODELLER PMID
25199792). In the structural model, 94 residues at the C termi-
nus as well as the residues between 510–562 were omitted
because of poor homology to the archaeal MCM. The MCM3
model was superimposed onto a published model of the
MCM2–7 heterohexamer from yeast (59) using PyMOL (The
PyMOL Molecular Graphics System, version 1.3, Schrödinger,
LLC). PyMOL was used to prepare the images used in Fig. 4, B
and C.
Affinity Purification and Mass Spectrometry—These experi-
ments were performed as described previously (19, 74, 76) with
minor modifications. Briefly, HEK293T cells (3–5  15-cm
plates) stably expressing either FLAG-MCM3 or SBPHA-
KEAP1 were lysed in 0.1% Nonidet P-40 lysis buffer for FLAG
IP or streptavidin AP, respectively. Cell lysates were incubated,
rotating with FLAG or streptavidin resin for 1 h at 4 °C, and
thenwashed three timeswith lysis buffer. The precipitated pro-
teins were then trypsinized (Promega) on beads at 37 °C over-
night (12–18 h) using the FASP protein digestion kit (Protein
Discovery). For the KEAP1 substrate-trapping experiment (Fig.
1, A and B), SBPHA-KEAP1-expressing HEK293T cells were
grown in SILACmedia (light, K0R0; heavy, K6R10) for at least 10
cell divisions prior to harvesting for lysis. Tryptic peptides were
cleaned up using a C18 spin column (Thermo Scientific) and
then separated by reverse-phase nano-HPLC using a nano-
Aquity ultra performance liquid chromatography (UPLC) sys-
tem (Waters Corp.). Chromatographic separation and mass
spectrometry analysis of peptides from FLAG-MCM3 experi-
ments (Fig. 2A) were performed using the same methods as in
our previous work (76). Peptides from SBPHA-KEAP1 and
ubiquitin remnant experiments were first trapped in a 2-cm
trapping column (Acclaim PepMap 100, C18 beads of 3.0-m
particle size, 100-Å pore size) and a 25-cm EASY-spray analyt-
ical column (75-m inner diameter, C18 beads of 2.0-m par-
ticle size, 100-Å pore size) at 35 °C. The flow rate was 250
nl/min over a gradient of 1% buffer B (0.1% formic acid in ace-
tonitrile) to 30% buffer B in 180 min, and an in-line Orbitrap
Elite mass spectrometer (Thermo Scientific) performed mass
spectral analysis. The ion source was operated at 2.4–2.8 kV
with the ion transfer tube temperature set at 300 °C. A full MS
scan (300–2000 m/z) was acquired in Orbitrap with a 120,000
resolution setting, and data-dependent MS2 spectra were
acquired in the linear ion trap by collision-induced dissociation
using the 15 most intense ions. Precursor ions were selected
based on charge states (3	2) and intensity thresholds (above
1e5) from the full scan; dynamic exclusion (one repeat during
30 s, a 60-s exclusion time window) was also used. The polysi-
loxane lock mass of 445.120030 was used throughout spectral
acquisition.
Protein Identification, Filtering, and Bioinformatics—For the
MCM3 protein interaction network (Fig. 2A), the raw mass
spectrometry data were searched with MaxQuant (1.5.2.6)
alongwith an internal lab FLAG affinity purificationmass spec-
trometry (APMS) dataset of an additional 17 baits and 35 exper-
iments. The search parameters were as follows: specific tryptic
digestion, up to twomissed cleavages, a static carbamidomethyl
cysteine modification, variable protein N-terminal acetylation,
and variable methionine oxidation using the human Uni-
ProtKB/Swiss-Prot sequence database (release 2013_07). Pro-
teinswere then filtered for a 1%protein level false discovery rate
(FDR). Filtering of false interactions was then accomplished
using Spotlite (19), with a 10% FDR for the entire dataset,
including the additional baits. These results were then
imported into Cytoscape v3.2.1 for network visualization. The
Spotlite results are provided in supplemental Table S2. For the
SBPHA-KEAP1 SILAC experiments, the additional MaxQuant
parameters were a variable Gly-Gly modification on lysines,
and Lys-6 and Arg-10 heavy SILAC labels. The Maxquant
results are provided in supplemental Table S1.
For ubiquitin remnant profiling, raw files were searched
using SorcererTM-SEQUEST (build 5.0.1, Sage N Research)
and the Transproteomic Pipeline (TPP v4.7.1). The search
parameters used were a precursor mass between 400 and 4500
amu, a maximum of two missed cleavages, a precursor ion tol-
erance of 3 atomic mass unit (amu), accurate mass binning
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within PeptideProphet, semitryptic digestion, a static carbam-
idomethyl cysteine modification (57.021465), and variable
methionine oxidation (	15.99492), ubiquitylated lysine
(114.042931), and serine, threonine and tyrosine (STY) phos-
phorylation (79.966331). A 1% peptide-level FDR was deter-
mined by PeptideProphet. The mass spectrometry proteomics
data have been deposited in the ProteomeXchangeConsortium
via the PRIDE (77) partner repositorywith the dataset identifier
PXD003929.
Ubiquitin Remnant Profiling—For mapping the ubiquity-
lated lysines within MCM3, immunoprecipitations for FLAG-
MCM3 were done under near-denaturing conditions in the
presence or absence of SBPHA-KEAP1. Then, the proteins
were subject to tryptic digest and the peptides were flowed over
beads conjugated to the ubiquitin remnant specific antibody
(Cell Signaling) for 4 h at 4°C in IAP buffer supplied by the
manufacturer. Beads were washed twice with IAP buffer and
once with PBS. Peptides were eluted with 0.15% TFA for 5 min
at room temperature and dried at room temperature by speed
vacuuming. Peptides were shot in the mass spectrometer as
described above. Ubiquitylated peptides identified by MS/MS
were then quantified in Skyline v3.5. For each peptide, theMS1
intensity of its extracted ion chromatogram was integrated for
each of 3 label-free replicate experiments (3 runswithKEAP1, 3
runs without KEAP1). Any peptide identified by MS/MS or
which was aligned by m/z, retention time, and had an isotope
dot product .8 was included in the analysis. The mean total
area of each MS1 belonging to a ubiquitylated MCM3 peptide
was taken from the 3 replicate experiments and a ratio was
created for the 	KEAP1/-KEAP1 conditions. For any peptide
found to be true in one condition, but that was missing in the
other, the background at the same mass to charge window was
quantified to calculate a-fold change. The complete results are
provided in Table S3. The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consortium via
the PRIDE (77) partner repository with the dataset identifier
PXD003929.
Immunostaining—These experiments were performed as
reported previously with minor modifications (76). To deter-
mine the subcellular distribution of KEAP1 and MCM3 pro-
teins, HEK293T cells stably expressing VENUS-KEAP1 were
plated on 10 g/ml fibronectin-coated coverslips in DMEM
supplemented with 10% fetal bovine serum and subjected to
staining. Cells were fixed in 4% paraformaldehyde in cytoskel-
etal buffer (5mMPIPES (pH6), 137mMNaCl, 5mMKCl, 1.1mM
Na2HPO4, 0.4 mMKH2PO4, 0.4 mMMgCl2, 0.4 mMNaHCO3, 2
mM EGTA, and 50 mM glucose) for 15 min and permeabilized
with 0.1% Triton X-100/PBS solution for 5 min. After blocking
with 1% BSA/PBS, cells were incubated overnight with a rabbit
polyclonal antibody againstMCM3 (Bethyl, 1:250 dilution), fol-
lowed by incubation with TRITC-conjugated donkey second-
ary antibody (1:300 dilution) against rabbit IgG. Coverslips
weremounted to slides using the ProlongGold antifade reagent
(Invitrogen/Molecular Probes), and images were acquired
using a Zeiss LSM710 confocal laser-scanning microscope
equipped with40/1.3 Oil Plan Neo and63/1.4 Oil Plan Apo
objective lenses.
Proximity Ligation Assays—For detection of KEAP1 and
MCM3 interactions, proximity ligationwas performedwith the
Duolink II proximity ligation assay kit according to the protocol
of the manufacturer (Sigma, DUO092101). Briefly, HEK293T
cells stably expressing VENUS-KEAP1 were plated, fixed, and
permeabilized as described above. Next, cells were incubated in
blocking solution in a humidified chamber at 37 °C for 30 min,
followed by overnight co-incubation with rabbit polyclonal
antibodies against MCM3 (Bethyl, 1:250) andmouse monoclo-
nal antibody against KEAP1 (Origene, 1:100) in antibody dilu-
ent solution at 4 °C. Cells were washed in buffer A and incu-
bated with PLA probes (PLA probe minus and plus in antibody
diluent, 1:5 dilution) for 1 h at 37 °C, washed in buffer A, and
incubated with ligation solution (1:5 dilution of ligation buffer
and 1:40 dilution of ligase in pure water) for 30 min at 37 °C.
After ligation, cell were washed in buffer A and subjected to
amplification with Detection Reagents Red from (1:5 dilution
amplification stock and 1:80 dilution of polymerase in water)
for 100 min at 37 °C. Amplified samples were washed in buffer
B and then mounted with Duolink II mounting medium with
DAPI. Confocal Z-stack images were acquired using a Zeiss
LSM710 spectral confocal laser-scanningmicroscope equipped
with a 63/1.42 Oil PlanApo objective lens. ImageJ software
was used to process the images to a two-dimensional illustra-
tion of all dots in each cell.
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